On April 21, 2026, Ionis Pharmaceuticals announced positive results for zilganersen in treating Alexander disease, showing significant improvement in gait speed and gross motor function among participants. The study met key endpoints, with 53 patients aged 2-53, demonstrating a 33.3% improvement in gait speed and favorable safety profile.